KR910001040A - 항응고요법을 위한 활성물질인 암블리옴민 - Google Patents

항응고요법을 위한 활성물질인 암블리옴민 Download PDF

Info

Publication number
KR910001040A
KR910001040A KR1019890007559A KR890007559A KR910001040A KR 910001040 A KR910001040 A KR 910001040A KR 1019890007559 A KR1019890007559 A KR 1019890007559A KR 890007559 A KR890007559 A KR 890007559A KR 910001040 A KR910001040 A KR 910001040A
Authority
KR
South Korea
Prior art keywords
ile
leu
protein
ser
glu
Prior art date
Application number
KR1019890007559A
Other languages
English (en)
Other versions
KR0138531B1 (ko
Inventor
보닌 베르너
하베르만 파울
트리피에르 도미니크
뵈너 엘리사벳
Original Assignee
하인리히 벡커, 베른하르트 벡크
훽스트 아크티엔게젤샤프트
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 하인리히 벡커, 베른하르트 벡크, 훽스트 아크티엔게젤샤프트 filed Critical 하인리히 벡커, 베른하르트 벡크
Publication of KR910001040A publication Critical patent/KR910001040A/ko
Application granted granted Critical
Publication of KR0138531B1 publication Critical patent/KR0138531B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43513—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae
    • C07K14/43527—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae from ticks
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/63—Arthropods
    • A61K35/646—Arachnids, e.g. spiders, scorpions, ticks or mites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/855—Proteins from animals other than mammals or birds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Insects & Arthropods (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

내용 없음.

Description

항응고요범을 위한 활성물질인 암블리옴민
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (10)

  1. 하드(hard) 참진드리로부터 분리된, 트롬빈 억제작용을 갖는 단백질 또는 이의 약제학적으로 허용되는 염.
  2. 제1항에 있어서, 분자량이 20000 내지 30000달톤이고, 등전점이 5.05 내지 5.65이며, 부분적인 아미노산 서열이 하기와 같은 단백질 또는 이의 약학적으로 허용되는 염.
    -Ile-Leu-Phe-Thr-Gln-Gly-Asn-X-Gly-Leu-Glu-Asn-X-Phe-Glu-, - Lys-Ile-Leu-Phe-X-Gln-Gly- 및 -Ala-Ser-Tyr-Ile-Val-X-Ser-Glu-Ser-Ile-Gln-Ile-Leu-X-Leu-Ser-Glu-Gly-Ile- 상기 서열에서, 래디칼 X는 각각 동일하거나 상이하며, 천연 아미노산이다.
  3. 제1항 또는 제2항에 있어서, 분자량이 26000±2000달톤인 단백질 또는 이의 약제학적으로 허용되는 염.
  4. 제1항 내지 제3항중 어느 한 항에 있어서, 등전점이 5.35인 단백질 또는 이의 약제학적으로 허용되는 염.
  5. 제1항 내지 제4항중 어느 한 항에서, 부분적인 아미노산 서열이 하기와 같은 단백질 또는 이의 약제학적으로 허용되는 염.
    -Ile-Leu-Phe-Thr-Gln-Gly-Asn-X-Gly-Glu-Asn-X-Phe-Glu. -Lys-Ile-Leu-Phe-X-Gln-Gly- 및 -Ala-Ser-Tyr-Ile-Val-X-Ser-Glu-Ser-Ile-Gln-Ile-Leu-X-Leu-Ser-Glu-Gly-Ile-
    상기 서열에서, 래디칼 X는 각각 동일하거나 상이하며, 각각 Tyr, Ser, Thr, Gln, Asp, Asn 또는 해독후 변형된 아미노산(예:트리메틸라이신 또는 카복시글루탐산)을 나타낸다.
  6. 제1항 내지 제5항중 어느 한 항에 있어서, 리세피세팔루스 에버트시(Rhipicephalus evertsi)로 부터 분리된 단백질 또는 이의 약제학적으로 허용되는 염.
  7. 제1항 내지 제3항에 있어서, 암블리옴마헤브레움(Amblyomma hebraeum)으로 부터 분리된 단백질 또는 이의 약제학적으로 허용되는 염.
  8. 추출방법 및 크로마토그래피 방법을 혼합사용하는 방법에 따라 분리공정을 수행하며, 경우에 따라 단백질을 효소적으로 분해시키고, 또한 경우에 따라, 생성된 단백질을 이의 생리학적으로 허용되는 염으로 전환시킴을 특징으로 하여, 제1항 내지 제7항중 어느 한 항에서 청구한 정체 단백질을 분리하는 방법.
  9. 제1항 내지 제7항중 어느 한 항에서 청구한 단백질의 약제로서의 용도.
  10. 제1항 내지 제7항중 어느 한 항에서 청구한 단백질의 향트롬빈제로서의 용도.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019890007559A 1988-06-04 1989-06-02 항응고요법을 위한 활성물질인 암블리옴민 KR0138531B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE3819078A DE3819078A1 (de) 1988-06-04 1988-06-04 Amblyommin, ein neuer wirkstoff fuer die antikoagulationstherapie
DEP3819078.8 1988-06-04
DE?P3819078.8? 1988-06-04

Publications (2)

Publication Number Publication Date
KR910001040A true KR910001040A (ko) 1991-01-30
KR0138531B1 KR0138531B1 (ko) 1998-04-30

Family

ID=6355878

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019890007559A KR0138531B1 (ko) 1988-06-04 1989-06-02 항응고요법을 위한 활성물질인 암블리옴민

Country Status (18)

Country Link
US (1) US5093322A (ko)
EP (1) EP0345614B1 (ko)
JP (1) JP2703993B2 (ko)
KR (1) KR0138531B1 (ko)
AT (1) ATE107666T1 (ko)
AU (1) AU618364B2 (ko)
CA (1) CA1339189C (ko)
DE (2) DE3819078A1 (ko)
DK (1) DK270489A (ko)
ES (1) ES2056149T3 (ko)
FI (1) FI93697C (ko)
HU (2) HU205148B (ko)
IE (1) IE64674B1 (ko)
IL (1) IL90508A (ko)
NO (1) NO175900C (ko)
NZ (1) NZ229401A (ko)
PT (1) PT90739B (ko)
ZA (1) ZA894181B (ko)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5385885A (en) * 1988-01-15 1995-01-31 Gasic; Gregory P. Inhibition of smooth muscle cell proliferation by antistasin and tick anticoagulant peptide
DE3931839A1 (de) * 1989-09-23 1991-04-04 Basf Ag Neue proteine und ihre herstellung
DE4136513A1 (de) * 1991-11-06 1993-05-13 Basf Ag Neues thrombininhibitorisches protein aus raubwanzen
US5321010A (en) * 1991-12-10 1994-06-14 Merck & Co., Inc. Proteins for inhibiting adhesion of platelets to collagen
CA2150909A1 (en) * 1992-12-04 1994-06-23 Christiane Noeske-Jungblut Clotting inhibitor made from protostomia saliva
GB2304048A (en) * 1995-08-12 1997-03-12 John William Carson Medicament containing saliva extract
US20050033022A1 (en) * 1997-09-26 2005-02-10 Smithkline Beecham Biologicals Sa Fusion proteins comprising HIV-1 Tat and/or Nef proteins
BRPI0406057B1 (pt) * 2004-09-15 2021-10-26 União Química Farmacêutica Nacional S/A Sequência nucleotídica de um inibidor de proteases do tipo kunitz obtida a partir de uma biblioteca de cdna de glândulas salivarares de carrapatos amblyomma cajennese uso da proteína recombinante
RU2740185C2 (ru) 2015-12-10 2021-01-12 Меникон Ко., Лтд. Пептидная композиция

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3438296A1 (de) * 1984-04-18 1985-11-07 Hoechst Ag, 6230 Frankfurt Neue polypeptide mit blutgerinnungshemmender wirkung, verfahren zu deren herstellung bzw. gewinnung, deren verwendung und diese enthaltende mittel
IL83912A (en) * 1986-09-18 1993-05-13 Pennsylvania Hospital Protein having anticoagulant and antimetastatic properties
US4832849A (en) * 1988-06-16 1989-05-23 Merrell Dow Pharmaceuticals Inc. Extraction and purification of an anticoagulant principle from the south american leech, haementeria ghilianii
CA2024697A1 (en) * 1989-09-07 1991-03-08 George P. Vlasuk Protein having anticoagulant properties

Also Published As

Publication number Publication date
AU618364B2 (en) 1991-12-19
FI892690A (fi) 1989-12-05
HUT52117A (en) 1990-06-28
CA1339189C (en) 1997-07-29
EP0345614A2 (de) 1989-12-13
DK270489D0 (da) 1989-06-02
FI93697C (fi) 1995-05-26
ZA894181B (en) 1990-02-28
NO892266L (no) 1989-12-05
DK270489A (da) 1989-12-05
HU205148B (en) 1992-03-30
PT90739B (pt) 1994-10-31
NO175900B (no) 1994-09-19
PT90739A (pt) 1989-12-29
NZ229401A (en) 1991-10-25
JPH0232100A (ja) 1990-02-01
IE891814L (en) 1989-12-04
NO892266D0 (no) 1989-06-02
NO175900C (no) 1994-12-28
AU3595489A (en) 1989-12-07
IL90508A (en) 1994-12-29
DE3819078A1 (de) 1989-12-07
FI93697B (fi) 1995-02-15
IE64674B1 (en) 1995-08-23
US5093322A (en) 1992-03-03
DE58907930D1 (de) 1994-07-28
KR0138531B1 (ko) 1998-04-30
JP2703993B2 (ja) 1998-01-26
IL90508A0 (en) 1990-01-18
EP0345614A3 (en) 1990-10-10
ES2056149T3 (es) 1994-10-01
HU210528A9 (en) 1995-04-28
ATE107666T1 (de) 1994-07-15
FI892690A0 (fi) 1989-06-01
EP0345614B1 (de) 1994-06-22

Similar Documents

Publication Publication Date Title
Burnett et al. The chemistry and toxicology of some venomous pelagic coelenterates
AU4159685A (en) Method of inhibiting and inducing human platelet aggregation
DE69027865D1 (de) ZUSAMMENSETZUNGEN enthaltend omega Conotoxin Peptide Derivate und deren Verwendung ZUR BEHANDLUNG VON ISCHÄMIE-ARTIGEN NEURONALEN SCHÄDIGUNGEN
ATE113846T1 (de) Therapeutische zusammensetzungen für die behandlung von myocard-infarkten.
WO1995021601A3 (en) Kallikrein-inhibiting 'kunitz domain' proteins and analogues thereof
ES8504246A1 (es) Un metodo para la preparacion de las proteasas fibrinoliticamente activas
KR910000171A (ko) 헤멘테리아 길리아니 거머리로부터 항응고 물질을 추출 및 정제방법
EP0348208A2 (en) Platelet-aggregating inhibitory agents from leech saliva and pharmaceutical preparations containing the same
KR910001040A (ko) 항응고요법을 위한 활성물질인 암블리옴민
DK0460062T3 (da) Huperzin A-analoger
DK610888D0 (da) Cardiodilatinfragmentet, fremgangsmaade til fremstilling deraf samt dets anvendelse
CA2006658A1 (en) An anticoagulant substance obtained from urine
KR950703004A (ko) 콜라겐-자극 혈소판 응집의 억제(inhibitor of collagen-stimulated platelet aggregation)
HUP9900506A2 (hu) Protrombinszármazékok
EP0225020A3 (en) Peptides comprising, in sequence, units selected from the amino-acid residues 17 to 24 of vip
DK482185D0 (da) Peptider, deres fremstilling og anvendelse som laegemidler
ES2171563T3 (es) Nueva familia de inhibidores de proteasas, y otras sustancias de actividad biologica.
EP0318233A3 (en) Improvements in or relating to serotonin and norepinephrine uptake inhibitors
IL95711A0 (en) Anticoagulant and anthelmintic proteins and methods for the production and use of the same
EP0373771A3 (en) New pharmaceutical uses for cystatins
BG90414A (bg) 2-азабицикло (2,2,1)-хепт-5- ен-2-оцетна киселина и нейни производни, метод за получаване и приложението им
EP0371733A3 (en) Dopamine-beta-hydroxylase inhibitors
ES2033295T3 (es) Un metodo para preparar un activador de plasminogeno.
SE8306792L (sv) Nytt terapeutiskt preparat innehallande hydrerade ergotalkaloider och heparin
BG102009A (en) Method for the treatment of manic and two-pole disease

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20040112

Year of fee payment: 7

LAPS Lapse due to unpaid annual fee